| Abstrakt: |
Background: Worldwide, colorectal cancer (CRC) is the third most common cancer and the second most common cause of cancer-related deaths. p21, inhibin, and Tob-1 are tumor suppressors that play a role in the development and progression of several cancers, however, their role in CRC is not well-established. This study aims to evaluate the expression of these proteins by immunohistochemistry and correlate their expression with the clinicopathological characteristics of CRCs and preneoplastic lesions [adenomas and ulcerative colitis] to study the potential for their use as targeted therapies. The study was performed on sections of 30 CRCs, 30 adenomas, 30 UC, 30 chronic colitis, and 20 controls. Results: p21 expression was lower in CRCs and adenomas compared to inflammatory lesions (chronic colitis and UC). High-grade CRCs, adenomas with high-grade dysplasia, and UC with dysplasia showed insignificantly lower expression compared to their counterparts. Inhibin expression was absent in CRCs; however, its expression was higher in chronic colitis than in UC and adenomas. Adenomas with high-grade dysplasia and UC with dysplasia showed insignificantly higher expression than their counterparts. Tob-1 expression increased significantly from chronic colitis to UC to adenomas to CRCs. High-grade CRCs, adenomas with high-grade dysplasia, and UC with dysplasia showed higher expression compared to their counterparts. Conclusions: Decreased p21 and increased inhibin and Tob-1 expressions are associated with the progression of adenomas and UC to more dysplastic lesions, then possibly to CRC. Despite being tumor suppressors, the studied proteins may potentially have tumor-promoting properties. They can be useful targets for therapeutic intervention. [ABSTRACT FROM AUTHOR] |
Full text from SpringerLink